Detalhe da pesquisa
1.
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer.
Cells
; 13(6)2024 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38534371
2.
PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer.
bioRxiv
; 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38464204
3.
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice.
Cell Death Discov
; 9(1): 1, 2023 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588105
4.
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers.
J Hematol Oncol
; 15(1): 23, 2022 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35260176
5.
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216.
Mol Cancer Ther
; 21(1): 184-192, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34667112
6.
DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
J Hematol Oncol
; 13(1): 95, 2020 07 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32677976
7.
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
Nat Commun
; 11(1): 1996, 2020 04 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32332723
8.
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.
Nat Med
; 25(12): 1938-1947, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31792461